title: Robust isolation of malignant plasma cells in multiple myeloma.
abstract: Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma. However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and systematically evaluated 7 candidates. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138 and enable isolation of myeloma plasma cells under more diverse conditions, including the samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.
authors.affiliation: Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Sweden;
authors.forename: Ildikó
authors.initials: I
authors.lastname: Frigyesi
authors.forename: Jörgen
authors.initials: J
authors.lastname: Adolfsson
authors.forename: Mina
authors.initials: M
authors.lastname: Ali
authors.forename: Mikael Kronborg
authors.initials: MK
authors.lastname: Christophersen
authors.forename: Ellinor
authors.initials: E
authors.lastname: Johnsson
authors.forename: Ingemar
authors.initials: I
authors.lastname: Turesson
authors.forename: Urban
authors.initials: U
authors.lastname: Gullberg
authors.forename: Markus
authors.initials: M
authors.lastname: Hansson
authors.forename: Björn
authors.initials: B
authors.lastname: Nilsson
mesh_terms: D053301:B-Cell Maturation Antigen / Q000032:analysis / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology*; D002469:Cell Separation / Q000379:methods*; D006801:Humans; D046228:Microarray Analysis; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D010950:Plasma Cells / Q000378:metabolism / Q000473:pathology*; D011971:Receptors, Immunologic / Q000032:analysis / Q000378:metabolism; D015203:Reproducibility of Results; D000071176:Signaling Lymphocytic Activation Molecule Family; D053668:Syndecan-1 / Q000032:analysis / Q000378:metabolism; D059467:Transcriptome
chemical_list: D053301:B-Cell Maturation Antigen; D014408:Biomarkers, Tumor; D011971:Receptors, Immunologic; C508241:SDC1 protein, human; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; D053668:Syndecan-1; C086966:TNFRSF17 protein, human